~~<i id='95BE3E9183'><strike id='95BE3E9183'><tt id='95BE3E9183'><pre id='95BE3E9183'></pre></tt></strike></i>~~

Home» explore» explore

explore

author：comprehensive 2025-09-30 09:08:16 Page View：4

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Spinal cord stimulation reduces pain in amputees, study finds
Next article： FDA approval of Sarepta Duchenne genetic therapy gives me hope

explore

Trump demands the U.S. pay no more for drugs than other countries … again

EthanMiller/GettyImagesWASHINGTON—FormerPresidentTrumpisbacktocampaigningfortyingMedicaredrugpricest

How Vertex's cystic fibrosis drug is changing patients' lives

SusanUlan,right,greetshergranddaughterIvy,andherdaughterJessieAnderson,atAnderson'shome.SuzanneKreit

The cancer drug shortage isn’t new — and neither are the solutions

PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

CDC's new outbreak response network to include Northeastern

MarkSchiefelbein/APNortheasternUniversityhasbeenselectedforaleadingroleinanewnationalnetworkformedto